ライフサイエンスコーパス: prescriber

1 a time frame other than that intended by the prescriber.

2 ons are written by multiple prescribers vs 1 prescriber.

3 quarters, attributed to the plurality opioid prescriber.

4 prescriptions from multiple prescribers vs 1 prescriber.

5 ns were written by multiple prescribers vs 1 prescriber.

6 bing pattern of a patient's most responsible prescriber.

7 h industry were similar to those reported by prescribers.

8 chart review and interview with patients and prescribers.

9 ate more effective education of these future prescribers.

10 nd agreement and participation by individual prescribers.

11 pulations having different patterns of using prescribers.

12 ed 32 opioid prescriptions from 10 different prescribers.

13 e treatment or primary care with hepatitis C prescribers.

14 estricting high daily dosage across multiple prescribers.

15 eractively to individuals or small groups of prescribers.

16 rs, with a monthly increase of 0.42 per 1000 prescribers.

17 deline compliance in groups of three or more prescribers.

18 nclear which agents should be prioritized by prescribers.

19 range of treatment options for patients and prescribers.

20 ions in 2018 vs 67.0% (49.9%-82.8%) for DOAC prescribers.

21 es; and 3 or more primary care buprenorphine prescribers.

22 t 1 prescription for buprenorphine from 1788 prescribers.

23 ), and with prescriptions from three or more prescribers.

24 a new opioid analgesic prescription from 490 prescribers.

25 medications often originated from different prescribers.

26 ous diseases physicians were the primary SAT prescribers.

27 ogram; and (5) disenrollment of noncompliant prescribers.

28 its may enhance care coordination with fewer prescribers.

29 included only publicly listed buprenorphine prescribers.

30 s who received treatment from high-intensity prescribers.

31 aused unnecessary concern among patients and prescribers.

32 eceived treatment from high-intensity opioid prescribers.

33 th systems, heightens the challenge faced by prescribers.

34 ence 11.8% (7.3%), and level of trust in the prescriber 11.4% (5.8%) had intermediate attribute impor

35 ram, 24 of 302 pharmacists (7.9%), 35 of 302 prescribers (11.6%), and 5 of 192 patients (2.6%) incorr

36 nic, noncancer pain; at 60 months, 54 of 302 prescribers (18.4%) and 148 of 310 patients (47.7%) erro

37 West [15%]), 103 practices (25.6%), and 540 prescribers (3.5%) had a higher proportion of patients w

38 In the 48-month survey, 106 of 310 prescribers (34.2%) reported prescribing TIRFs for opioi

39 ved the provision of 1357 medications (nurse prescribers=399, 54%; patient group directions=480, 51%)

40 ice were comparable (maximum score 46: nurse prescribers=44.7; patient group direction=45.4, p=0.41).

41 ectively; p=0.001); most were 'minor' (nurse prescribers=489, 56%; patient group directions=602, 62%)

42 alendar quarter); 8% had four or more opioid prescribers; 5% had prescriptions yielding a daily MED o

43 In 2013, among 91 837 prescribers, 54 501 (59.3%) prescribed only warfarin, 19

44 ely between low-intensity and high-intensity prescribers (7.3% vs. 24.1%).

45 Of 1682 clinical notes (nurse prescribers=743, 44%; patient group directions=939, 56%)

46 being high-intensity or low-intensity opioid prescribers according to relative quartiles of prescribi

47 term use attributed to region, practice, and prescriber, accounting for case mix and chance variation

48 nd obtain patient signatures on the "Patient-Prescriber Acknowledgement Form." A single, national, vo

49 386 LAI cabotegravir and rilpivirine prescribers across 28 countries completed the survey, re

50 e (1.5%) lower than the national mean of all prescribers across all medical specialties (6.8%).

51 o 100 for patients who had a continuation of prescriber (adjusted difference 1.22 percentage points,

52 than among patients treated by low-intensity prescribers (adjusted odds ratio, 1.30; 95% confidence i

53 Informed consent and patient-prescriber agreements are important strategies to ensure

54 'Observation study' involved 15 nurse prescriber and 15 patient group direction user nurse-pat

55 fied if they saw the nurse as diagnostician, prescriber and medical manager of the condition.

56 and dose of initial opioid prescriptions in prescriber and patient subgroups.

57 Having a usual preoperative opioid prescriber and visiting this prescriber within 30 days a

58 ts who received treatment from low-intensity prescribers and 161,951 patients who received treatment

59 ber 2015, 743 consultations managed by nurse prescribers and 939 consultations by patient group direc

60 Education among prescribers and a standardized approach with patient-spe

61 Significant disparities in access to active prescribers and DATA waiver prescribers persist between

62 The association between multiple prescribers and increased risk of overdose persisted in

63 differences in barriers experienced between prescribers and nonprescribers were "Getting started" an

64 Strategies that include frontline prescribers and other unit-based healthcare providers ha

65 We compared nurse prescribers and patient group direction users in terms o

66 Both nurse prescribers and patient group direction users made safe

67 Sexual health nurse prescribers and patient group direction users provided s

68 teness of medication provision between nurse prescribers and patient group direction users.

69 y/appropriateness was compared between nurse prescribers and patient group direction users.

70 supporting expedited authorisations so that prescribers and patients appreciate shortcomings in the

71 ent, the majority of analgesics available to prescribers and patients are based on mechanistic classe

72 Randomised assignments were concealed from prescribers and patients but not masked as the test resu

73 cy makers should consider ways to discourage prescribers and patients from requesting branded dispens

74 Prescribers and patients motivated 30.4% of all branded

75 ounty-level monthly numbers of buprenorphine prescribers and patients receiving buprenorphine (per 10

76 ed with a temporal increase in buprenorphine prescribers and patients receiving buprenorphine.

77 Prescribers and patients should consider the potential c

78 Use of multiple prescribers and pharmacies is a means by which some indi

79 independently associated with the number of prescribers and pharmacies that individuals used for pre

80 d physician availability) with the number of prescribers and the number of pharmacies that an individ

81 al establishment, (2) licensure criteria for prescribers and therapists, (3) clinical and billing inf

82 nd surgeons were associated with use of more prescribers and/or more pharmacies for obtaining prescri

83 Health workers perceive that prescribers' and dispensers' communication with patients

84 sed against the Prescribing Framework, nurse prescribers' and patient group directions users' clinica

85 s (obtained from a national database of PrEP prescribers) and pharmacies (obtained from state pharmac

86 ionship with staff (especially the physician-prescriber), and the patient's admission experience (max

87 alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions

88 or implementation across regulatory, policy, prescriber, and consumer spheres, portends an era of sig

89 can only be done safely if initiated by the prescriber, and in well-informed and prepared patients.

90 ing the intervention and control arms, site, prescriber, and patient characteristics were similar.

91 tive decision that involves the patient, the prescriber, and the eye care clinician and that focuses

92 patents, promote sales, and advise patients, prescribers, and dispensers.

93 h increasing numbers of nurse and pharmacist prescribers, and improving shared inter-professional acc

94 ng to the TIRF REMS, surveys of pharmacists, prescribers, and patients reflected generally high level

95 (1) Knowledge assessments of pharmacists, prescribers, and patients; (2) survey and claims-based p

96 ulatory decision makers, including patients, prescribers, and payers, because regulatory trials do no

97 risk communication was sent directly to all prescribers, and specifically recommended review of all

98 Prescribers are encouraged to educate patients receiving

99 Prescribers are responsible for determining whether PPI

100 y structure revealing inherent clustering of prescribers as a result of patient movement, and were ma

101 Although rulings cited prescribers as the prime target of off-label promotion,

102 emains an important topic of concern for all prescribers as well as drug manufacturers.

103 or national legislations aimed at increasing prescriber awareness and patient education on opioid use

104 Increasing patient and prescriber awareness in understanding patterns of ICI-MA

105 ong term opioid treatment who did not lose a prescriber, before and after prescriber exit.

106 a noncompliance plan, there was no report of prescribers being disenrolled for inappropriate prescrib

107 beta=0.028), and having three or more opioid prescribers (beta=0.046).

108 treatment durations recommended by different prescribers can improve antibiotic prescribing.

109 Increasingly, prescribers can use real-time prescription drug benefit

110 ments on drugs with important risks, such as prescriber certification or routine laboratory testing,

111 Secondary outcomes included prescriber characteristics and factors associated with r

112 Patient and prescriber characteristics are described, including pati

113 Exposures included patient and prescriber characteristics.

114 availability of youth-oriented services and prescribers comfortable treating this population.

115 ior, and facilitate targeted surveillance of prescriber communities.

116 only 4 state policies addressed governance, prescriber credentials, dispensing practices, and compou

117 expansion status and fibrosis, sobriety, and prescriber DAA restrictions.

118 This economic analysis used Medicare Part D prescriber data on drug prescriptions from 2013 to 2022

119 ers prescribing metformin in Medicare part D prescriber data.

120 analyzed using 2013 to 2015 Medicare Part D Prescriber Data.

121 managing numerous medications from multiple prescribers demand a comprehensive approach to mitigate

122 Information on patient and prescriber demographic characteristics, quantity of cene

123 randed PGA prescribing rate, controlling for prescriber demographic factors, local area practices, to

124 to $20.3 billion, including $5.6 billion for prescriber detailing, $13.5 billion for free samples, $9

125 Pharmacy independent prescribers developed a pharmaceutical care plan for eac

126 de because of slips in attention, or because prescribers did not apply relevant rules.

127 Many buprenorphine prescribers did not offer new appointments or rapid bupr

128 ntrol group received opioid prescriptions at prescribers' discretion.

129 Attorney General Consumer and Prescriber Education grant program, the Robert Wood John

130 Institute and Attorney General Consumer and Prescriber Education Program.

131 Besides prescriber education, policy makers may need to consider

132 immunity from civil liability for staff and prescribers, ensuring pharmacy laws allow prescriptions

133 from 132 to 229 per 10 000 patients who had prescriber exit from the quarter before to the quarter a

134 Across all four quarters after prescriber exit, an increase was reported in the rate of

135 did not lose a prescriber, before and after prescriber exit.

136 A poor relationship with the prescriber, experience of coercion during admission, and

137 Although prescribers face numerous patient-centered challenges du

138 es and regular point-prevalence surveys with prescriber feedback.

139 ducational interviews between counselors and prescribers from all departments to reinforce the princi

140 0.99 (95% CI, 0.94-1.04) for the patient and prescriber group and 1.00 (95% CI, 0.96-1.06) for the pr

141 If all branded dispensing requested by prescribers had been substituted by the corresponding ge

142 audit with feedback; however, engagement of prescribers has not been fully explored.

143 It is not clear how prescribers have responded to these warnings.

144 id cohort; the number of concurrent multiple-prescriber high-dosage episodes in a long-term opioid co

145 Prescribers identify with the clinical groups in which t

146 (n = 78) to 16% (n = 1789) of buprenorphine prescribers in 2017 and 2022, respectively (P < .001).

147 across regions and especially practices and prescribers in high-risk prescribing was observed.

148 iated with decreased odds of having multiple prescribers in the postoperative period.

149 ird (185/566; 32.7%) of pharmacy independent prescriber interventions involved medicines associated w

150 prevented, and communication with outpatient prescribers is vital.

151 product switches are likely to occur without prescriber knowledge and may pose a significant patient

152 ded the subset of adults (n = 1813) for whom prescriber knowledge, attitudes, and behavior survey dat

153 el claims with evidence context improved the prescribers' knowledge and reduced enthusiasm for the un

154 t of Clostridioides difficile infection, but prescribers lack quantitative information on comparative

155 t antibiotic orders, provide feedback to the prescribers, learn the mechanics and requirements of an

156 ved long term opioid treatment and who had a prescriber leave the workforce to propensity-matched pat

157 Providing clinic- and prescriber-level deimplementation strategies may help he

158 d to add prescriber peer consulting (PPC), a prescriber-level strategy focused on challenging patient

159 ies were targeted at the system, clinic, and prescriber levels.

160 Out-of-pocket cost varied by prescriber location and patient characteristics; mean co

161 n and quality of care provided by low-volume prescribers (LVPs) based on available data sources in Ne

162 76.7% (95% CI, 75.4-78.0) in the patient and prescriber mailing group, 77.9% (95% CI, 76.5-79.1) in t

163 ling group, 77.9% (95% CI, 76.5-79.1) in the prescriber mailing only group, and 77.5% (95% CI, 76.2-7

164 y 1, 2010, to December 31, 2012) linked with prescriber market data.

165 al need for opioids who use large numbers of prescribers may signal dangerously uncoordinated care.

166 ical situation requires a medication change, prescribers may want to take steps to optimize current m

167 Fulfillment trends were disaggregated by prescriber modality and state policy environment; 2 stat

168 contexts mirrored the overall trends, while prescriber modality trends were unique, with a big spike

169 ate ratio [RR], 0.85; 95% CI, 0.83-0.87) per prescriber-month when the electronic prompts were implem

170 ine milligram equivalents (MMEs) ordered per prescriber-month, prompts-targeted objectives, and unint

171 does not permit biosimilar substitution, as prescribers must include the product name on each prescr

172 Prescribers must understand the clinical outcomes of met

173 another, initiated outside the scope of the prescriber, must be avoided as they are unsafe.

174 promotional tactic was attempts to influence prescribers (n = 72, 97%), using print material (70/72,

175 companies lodged the majority of complaints (prescriber: n = 16, 22%, versus companies: n = 42, 57%).

176 the interest of minimizing risk to patients, prescribers need evidence indicating how these pharmacot

177 of potentially serious adverse consequences, prescribers need to evaluate the evidence objectively to

178 nterest in this population, as a new base of prescribers now work to incorporate the drug into clinic

179 nation between a patient's surgeon and usual prescriber of long-term opioid therapy could mitigate hi

180 es in Switzerland who were among the top 75% prescribers of antibiotics.

181 oners and gynecologists were the most common prescribers of azithromycin and ceftriaxone during the p

182 In this survey study of physician prescribers of clozapine, a majority were satisfied with

183 Consequently, the FDA determined that prescribers of FMT must possess an approved investigatio

184 highest-volume primary care physician (PCP) prescribers of quetiapine in original Medicare.

185 k of infection from resistant organisms, yet prescribers often fail to incorporate these results into

186 tering the order, who could then consult the prescriber on alternative therapies and implement more i

187 r group and 1.00 (95% CI, 0.96-1.06) for the prescriber only group compared with the usual care group

188 dy aimed to evaluate the association between prescribers' opioid prescribing history and persistent p

189 Branded dispensing requested by prescribers or patients incurred an incremental annual c

190 h an increase in the number of buprenorphine prescribers or patients receiving buprenorphine.

191 n, including the need to travel to certified prescribers or pharmacies.

192 sly provide medications as independent nurse prescribers or using patient group directions.

193 dds of receiving prescriptions from multiple prescribers (OR 0.80, 95% CI 0.68-0.95).

194 e likely to have prescriptions from multiple prescribers (OR 2.23 95% CI 1.75-2.83) and new long acti

195 enorphine prescribing rate per 1000 Medicaid prescribers, overall and by specialty.

196 in the 90-day postoperative period (multiple prescribers, overlapping opioid and/or benzodiazepine pr

197 lent (OME)] were performed at the specialty, prescriber, patient, and procedure levels.

198 es; and more effectively educating patients, prescribers, payers, and policy makers about these choic

199 has become a source of concern for patients, prescribers, payers, and policy makers.

200 alf the clinics were again randomized to add prescriber peer consulting (PPC), a prescriber-level str

201 ns, infants and children </= 2 years of age, prescribers per capita, and females were more likely to

202 access to active prescribers and DATA waiver prescribers persist between rural and urban areas in Cal

203 for inclusion were: Registered Nurses, nurse prescribers, Physician Assistants, pharmacists, dieticia

204 Analysis incorporating prescriber practice information found lower failure to r

205 bing in long-term care settings is driven by prescriber preferences and is associated with preventabl

206 ce of beneficiaries with four or more opioid prescribers, prescriptions yielding a daily morphine-equ

207 Secondary measures included spironolactone prescriber profiles and potassium monitoring practices.

208 hysician organizations in the development of prescriber profiling is directly relevant to the contemp

209 Each pharmacy independent prescriber provided pharmaceutical care to approximately

210 Prescriber provision of extended supply rose modestly wi

211 Medicare Part D 2013 prescriber public use file and summary file were used to

212 ims and spending dashboards, Medicare Part D Prescriber Public Use File, and SSR Health for the top 4

213 pective cost analysis of the Medicare Part D Prescriber Public Use File, which details annual drug ut

214 dicare and Medicaid Services Medicare Part D Prescriber Public Use Files for 2013, 2014, 2015, and 20

215 dicare and Medicaid Services Medicare Part D Prescriber Public Use Files for 2013, 2014, and 2015 wer

216 ptions written annually by ophthalmologists; prescriber rates compared with all prescriptions written

217 cluding refills, number of days' supply, and prescriber rates) for all participating ophthalmologists

218 s to reproductive psychiatry curricula among prescribers, reduce perinatal mental health and obstetri

219 15 to August 2016 to describe PrEP patients, prescribers, relative uptake, and payment methods in the

220 unt on generic vs branded, 73.9% [26.9%] for prescriber requests).

221 4 million claims (16.9%) occurred because of prescriber requests; and 1.1 million claims (13.5%) occu

222 Restricted access to opioids, prescriber restriction laws, and a low prevalence of mor

223 Compared with no prescriber restrictions (97.8 per 100 000 Medicaid recip

224 ams have implemented fibrosis, sobriety, and prescriber restrictions to control costs.

225 us and categories of fibrosis, sobriety, and prescriber restrictions.

226 ent, medications prescribed, and prescribing prescriber's clinic care modality (in-person only, hybri

227 sex, generic vs name brand formulations, and prescriber's location) were examined by payer type.

228 However, whether and how the prescriber's opioid prescribing behavior impacts persist

229 diates the relationship between race and the prescriber's opioid selection; and whether the chosen op

230 g perceived as a diversion risk due to their prescriber's physical distance from the pharmacy.

231 on the opioid-specific risk of NOWS may help prescribers select opioids for pain management in late s

232 Prescribers sent prescription requests to the online pha

233 ce improvement initiatives should target all prescriber settings and not just behavioral health.

234 UK prescribers should be attentive to, and increasingly rep

235 s will qualify for second line therapies and prescribers should be aware of the indications to use th

236 Prescribers should be aware that many adults prescribed

237 Prescribers should be mindful of diabetes risks when tre

238 Prescribers should carefully re-introduce CNI after the

239 Primary care clinics with MOUD prescribers should consider implementing CCM for OUD and

240 ophylaxis is used during eculizumab therapy, prescribers should consider trends in gonococcal antimic

241 Prescribers should preferentially use lower-risk antibio

242 Antimalarial prescribers should prescribe antimalarial dosages at 5 m

243 Nevertheless, prescribers should remain vigilant for this potential dr

244 ensity deimplementation strategy targeted at prescribers significantly decreased the MME dose and inc

245 Taxonomy enrichment of the prescriber specialties in PPN using chi-square test reve

246 significant reductions were seen across all prescriber specialties.

247 Incident prescriptions by drug class (by prescriber specialty, patient age, and sex) and drug.

248 d with approval/abandonment including payor, prescriber specialty, pharmacy benefit manager, out-of-p

249 However, the initiating prescriber specialty-setting was not associated with lip

250 ted antipsychotic medication in a variety of prescriber specialty-settings: 24.3%, community mental h

251 and by agent, class, patient age, state, and prescriber specialty.

252 the label changes, overall and stratified by prescriber specialty.

253 Prescriber surveys were disseminated by neurocritical ca

254 her among patients treated by high-intensity prescribers than among patients treated by low-intensity

255 ) but rated their peers as more conservative prescribers than themselves (median, 3; IQR, 2 to 5).

256 s integrated into the workflow of nurses and prescribers that facilitate review of antibiotic use, an

257 nstrated that patients with most responsible prescribers that historically prescribed higher daily do

258 -days (62.5%) involving prescriptions from 1 prescriber, there were 1302 overdoses (3.9 per 100 000 p

259 37.5%) involving prescriptions from multiple prescribers, there were 1390 overdoses (7.0 per 100 000

260 ied was broad enough to allow the antibiotic prescriber to choose a regimen based on additional crite

261 nce for opioid agonist therapy (OAT) allowed prescribers to increase the number of take-home doses to

262 thirds of states have restrictions based on prescriber type, and 88% include drug or alcohol use in

263 to liver disease staging, HIV co-infection, prescriber type, and drug or alcohol use across the Unit

264 ries: liver disease stage, HIV co-infection, prescriber type, and drug or alcohol use.

265 es were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions.

266 pharmacy who could benefit from therapy, but prescriber uncertainty surrounding the appropriate manag

267 s Administration (SAMSHA)-listed DATA waived prescribers under each 5-digit ZIP Code.

268 igation strategy (REMS), which mandates that prescribers undergo a certification process in which the

269 The incidence rates of new prescriber use and new pharmacy use for opioid prescript

270 Males had a lower incidence rate of new prescriber use and new pharmacy use than females.

271 lls for action for reduction in practice and prescriber variation by promoting safe practice in opioi

272 the extent to which regions, practices, and prescribers vary in opioid prescribing whilst accounting

273 overlap involved prescriptions from multiple prescribers vs 1 prescriber, was calculated.

274 apping prescriptions are written by multiple prescribers vs 1 prescriber.

275 verlap involving prescriptions from multiple prescribers vs 1 prescriber.

276 these prescriptions were written by multiple prescribers vs 1 prescriber.

277 d treatment, perceived relationship with the prescriber, ward atmosphere, and admission experience.

278 similar dosages, regardless of whether their prescriber was a primary care physician or a psychiatris

279 CMHC (0.74 [0.64-0.85]) or if the initiating prescriber was a primary care practitioner (0.81 [0.66-1

280 rement for advanced fibrosis or a specialist prescriber, was associated with increased treatment rate

281 prescriptions from multiple prescribers vs 1 prescriber, was calculated.

282 ional survey data from 787 expert antibiotic prescribers, we run computer simulations to test the per

283 rescription, and having three or more opioid prescribers were each negatively associated with uninten

284 e prescription in CURES and their California prescribers were eligible for inclusion.

285 Antihyperglycemic medication prescribers were identified as those physicians and adva

286 Nurse prescribers were more likely to make an error compared t

287 Prescribers were randomized 1:1 to either a 12-month int

288 Prescribers were randomized 1:1 to either a 12-month int

289 throughout the study compared with 2013 DOAC prescribers, which represents a median (IQR) of 41.9% (2

290 ations who are vulnerable to infection, have prescribers who are often off-site, and have limited acc

291 We interviewed the prescribers who made 44 of these, and analysed our findi

292 of primarily prescribing branded PGAs among prescribers who reported receiving no TOV was 12.9% (95%

293 Our results suggest that prescriber with a history of prescribing a higher opioid

294 predictors of premature discontinuation were prescriber, with patients of general practitioners demon

295 ed for a growing percentage of buprenorphine prescribers, with a monthly increase of 0.42 per 1000 pr

296 s treated by high-intensity or low-intensity prescribers, with adjustment for patient characteristics

297 perative opioid prescriber and visiting this prescriber within 30 days after surgery was associated w

298 as a normal (ie, prescribed by an authorized prescriber without additional certification or registrat

299 Key issues were diversifying the prescriber workforce, the importance of continuity of re

300 ist to increase access by using the existing prescriber workforce.